Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Immuno-Grade DP1 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Immunohistochemical identification of DP1 Prostanoid receptor 1 in kidney
DP1 (IHC-grade), DP1 Prostanoid Receptor Antibody
The non-phospho-DP1 Receptor Antibody is directed against the distal end of the carboxyl-terminal tail of human DP1. It can be used to detect total DP1 receptors in Western blots independent of phosphorylation. The non-phospho-DP1...
$ 375.00 *
Details

The DP1 receptor, also known as the prostaglandin D2 receptor (PTGDR), is a class A G protein–coupled receptor that binds prostaglandin D2 (PGD2) with high affinity. It is primarily coupled to Gs proteins, leading to activation of adenylyl cyclase, increased intracellular cAMP levels, and downstream signaling through protein kinase A (PKA). In certain contexts, DP1 signaling can also modulate immune cell function by influencing cytokine production and cellular migration. The receptor is expressed in various tissues, including the brain, immune cells (such as Th2 cells and eosinophils), platelets, and vascular smooth muscle, where it contributes to inflammatory and vascular regulation. DP1 plays an important role in allergic responses, asthma pathophysiology, and sleep regulation, reflecting the diverse biological functions of PGD2. Pharmacologically, DP1 antagonism has been explored for therapeutic purposes; for example, the selective DP1 antagonist laropiprant was developed to reduce flushing associated with niacin therapy, although it is no longer widely used clinically. Additional selective DP1 antagonists have been studied in preclinical and early clinical research, particularly in the context of allergic and inflammatory diseases. Ongoing investigations continue to evaluate the therapeutic potential of modulating DP1 signaling in respiratory and immune-mediated disorders. For more information on prostanoid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994 Jun;46(2):205-29. PMID: 7938166.

Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011 Sep;63(3):471-538. doi: 10.1124/pr.110.003517. PMID: 21752876.

The DP1 receptor, also known as the prostaglandin D2 receptor (PTGDR), is a class A G protein–coupled receptor that binds prostaglandin D2 (PGD2) with high affinity. It is primarily coupled to Gs... read more »
Close window
Immuno-Grade DP1 Receptor Antibodies

The DP1 receptor, also known as the prostaglandin D2 receptor (PTGDR), is a class A G protein–coupled receptor that binds prostaglandin D2 (PGD2) with high affinity. It is primarily coupled to Gs proteins, leading to activation of adenylyl cyclase, increased intracellular cAMP levels, and downstream signaling through protein kinase A (PKA). In certain contexts, DP1 signaling can also modulate immune cell function by influencing cytokine production and cellular migration. The receptor is expressed in various tissues, including the brain, immune cells (such as Th2 cells and eosinophils), platelets, and vascular smooth muscle, where it contributes to inflammatory and vascular regulation. DP1 plays an important role in allergic responses, asthma pathophysiology, and sleep regulation, reflecting the diverse biological functions of PGD2. Pharmacologically, DP1 antagonism has been explored for therapeutic purposes; for example, the selective DP1 antagonist laropiprant was developed to reduce flushing associated with niacin therapy, although it is no longer widely used clinically. Additional selective DP1 antagonists have been studied in preclinical and early clinical research, particularly in the context of allergic and inflammatory diseases. Ongoing investigations continue to evaluate the therapeutic potential of modulating DP1 signaling in respiratory and immune-mediated disorders. For more information on prostanoid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994 Jun;46(2):205-29. PMID: 7938166.

Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011 Sep;63(3):471-538. doi: 10.1124/pr.110.003517. PMID: 21752876.

Recently viewed